CN103110603B - 一种头孢克洛分散片及其制备方法 - Google Patents
一种头孢克洛分散片及其制备方法 Download PDFInfo
- Publication number
- CN103110603B CN103110603B CN201310044280.1A CN201310044280A CN103110603B CN 103110603 B CN103110603 B CN 103110603B CN 201310044280 A CN201310044280 A CN 201310044280A CN 103110603 B CN103110603 B CN 103110603B
- Authority
- CN
- China
- Prior art keywords
- cefaclor
- pellet
- drug
- disintegrating agent
- medicine carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005361 cefaclor Drugs 0.000 title claims abstract description 64
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 title claims abstract 14
- 238000002360 preparation method Methods 0.000 title claims description 15
- 239000007919 dispersible tablet Substances 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000008188 pellet Substances 0.000 claims abstract description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 15
- 239000008101 lactose Substances 0.000 claims abstract description 15
- 239000000725 suspension Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 238000007907 direct compression Methods 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 229960004756 ethanol Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 235000019890 Amylum Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 10
- 238000004090 dissolution Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract 2
- 238000005303 weighing Methods 0.000 abstract 1
- WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 description 50
- 238000005516 engineering process Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 3
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229950005770 hyprolose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310044280.1A CN103110603B (zh) | 2013-01-31 | 2013-01-31 | 一种头孢克洛分散片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310044280.1A CN103110603B (zh) | 2013-01-31 | 2013-01-31 | 一种头孢克洛分散片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103110603A CN103110603A (zh) | 2013-05-22 |
CN103110603B true CN103110603B (zh) | 2014-07-02 |
Family
ID=48409004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310044280.1A Active CN103110603B (zh) | 2013-01-31 | 2013-01-31 | 一种头孢克洛分散片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103110603B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800298A (zh) * | 2014-01-23 | 2014-05-21 | 刘燕 | 一种头孢克洛咀嚼片及其制备方法 |
CN113750066B (zh) * | 2021-10-12 | 2022-12-02 | 上海金城素智药业有限公司 | 一种具有临床优势的头孢克洛制剂及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009762A1 (en) * | 1992-11-05 | 1994-05-11 | Merck & Co., Inc. | Drug delivery device |
CN1380829A (zh) * | 2000-05-26 | 2002-11-20 | 韩美药品工业株式会社 | 可迅速崩解的片剂及其制备方法 |
-
2013
- 2013-01-31 CN CN201310044280.1A patent/CN103110603B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009762A1 (en) * | 1992-11-05 | 1994-05-11 | Merck & Co., Inc. | Drug delivery device |
CN1380829A (zh) * | 2000-05-26 | 2002-11-20 | 韩美药品工业株式会社 | 可迅速崩解的片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103110603A (zh) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101474175A (zh) | 一种高生物利用度非布司他口服固体制剂及其制备方法 | |
CN104940158B (zh) | 一种含有头孢呋辛酯的药物组合物 | |
CN103479592B (zh) | 一种盐酸二甲双胍缓释片及其制备方法 | |
CN102058561B (zh) | 头孢地尼胶囊及其制备方法 | |
CN105412036A (zh) | 依匹哌唑口腔崩解片 | |
CN104146978B (zh) | 一种双硫仑肠溶片剂及其制备方法 | |
CN104586854B (zh) | 头孢呋辛酯药物组合物及其制备方法 | |
JP2007211006A (ja) | 溶出安定性を有するコーティング固形製剤 | |
CN102362863B (zh) | 一种含奥利司他的制剂及其制备方法 | |
CN103110603B (zh) | 一种头孢克洛分散片及其制备方法 | |
CN102727452A (zh) | 一种含右佐匹克隆的颗粒及其制备方法 | |
CN102688210A (zh) | 鲁拉西酮的药物组合物和制备方法 | |
CN101836994A (zh) | 一种头孢克洛与溴己新复方口服制剂及其制备方法 | |
CN105343028A (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
CN104688698B (zh) | 一种头孢妥仑匹酯片剂 | |
CN103145733B (zh) | 一种阿莫西林化合物及该化合物和克拉维酸钾的药物组合物 | |
CN103006604B (zh) | 一种头孢呋辛酯片及其制备方法 | |
CN106377514A (zh) | 盐酸鲁拉西酮分散片 | |
CN102327266A (zh) | 一种含有伊潘立酮的药物组合物及其制备方法 | |
CN103142659B (zh) | 一种含白葡奈氏菌的膜包衣片剂 | |
CN103040788A (zh) | 一种头孢呋辛酯胶囊及其制备方法 | |
CN103070839A (zh) | 一种西他沙星片剂及其制备方法 | |
CN102688209A (zh) | 鲁拉西酮片和制备方法 | |
CN102138923B (zh) | 盐酸头孢卡品酯组合物及其制备方法 | |
CN102920678B (zh) | 一种高吸收及高生物利用度的奥氮平固体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 314033 No. 340, Yun Hai Road, Jiaxing Economic Development Zone, Zhejiang, China Patentee after: Beck Norton (Zhejiang) Pharmaceutical Co.,Ltd. Address before: 314033 No. 340, Yun Hai Road, Jiaxing Economic Development Zone, Zhejiang, China Patentee before: ZHEJIANG HOLLEY NANHU PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Cefaclor dispersible tablet and preparation method thereof Effective date of registration: 20170220 Granted publication date: 20140702 Pledgee: Industrial Commercial Bank of China Ltd. Jiaxing branch Pledgor: Beck Norton (Zhejiang) Pharmaceutical Co.,Ltd. Registration number: 2017330000015 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200623 Granted publication date: 20140702 Pledgee: Industrial Commercial Bank of China Ltd. Jiaxing branch Pledgor: Beck Norton (Zhejiang) Pharmaceutical Co.,Ltd. Registration number: 2017330000015 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Cefaclor dispersible tablet and preparation method thereof Effective date of registration: 20200628 Granted publication date: 20140702 Pledgee: Industrial Commercial Bank of China Ltd. Jiaxing branch Pledgor: Beck Norton (Zhejiang) Pharmaceutical Co.,Ltd. Registration number: Y2020330000403 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230724 Granted publication date: 20140702 Pledgee: Industrial Commercial Bank of China Ltd. Jiaxing branch Pledgor: Beck Norton (Zhejiang) Pharmaceutical Co.,Ltd. Registration number: Y2020330000403 |